2. Search Result
Search Result
Results for "

Cachexia

" in MedChemExpress (MCE) Product Catalog:

53

Inhibitors & Agonists

1

Biochemical Assay Reagents

5

Peptides

2

Inhibitory Antibodies

4

Natural
Products

4

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-N0109
    Salidroside
    Maximum Cited Publications
    44 Publications Verification

    Rhodioloside

    		 PINK1/Parkin mTOR Apoptosis Prolyl Endopeptidase (PREP) Cancer
    Salidroside (Rhodioloside) is a prolyl endopeptidase inhibitor. Salidroside alleviates cachexia symptoms in mouse models of cancer cachexia via activating mTOR signalling. Salidroside protects dopaminergic neurons by enhancing PINK1/Parkin-mediated mitophagy.
    Salidroside
  • HY-112288
    C188-9
    30+ Cited Publications

    TTI-101

    		 STAT Apoptosis DNA Methyltransferase Metabolic Disease Inflammation/Immunology Cancer
    C188-9 (TTI-101) is a STAT3 inhibitor with a Kd value of 4.7 nM. C188-9 targets the SH2 domain of STAT3, blocks the processes of STAT3 ligand binding, receptor recruitment, homodimerization and phosphorylation, and regulates STAT3-mediated genes associated with tumorigenesis and radioresistance. C188-9 regulates STAT1-mediated genes related to radioresistance and reduces the activation level of STAT1. C188-9 downregulates the expression of DNMT1, enhances DAC-induced demethylation and re-expression of RASSF1A, and simultaneously potentiates the anti-tumor effect of DAC on pancreatic cancer cells. C188-9 inhibits both anchorage-dependent and anchorage-independent growth of cancer cells, induces Apoptosis, blocks the growth of tumor xenografts, and suppresses muscle atrophy. C188-9 maintains muscle mass, increases body weight and improves grip strength in tumor-bearing mice. C188-9 can be used in research related to head and neck squamous cell carcinoma, pancreatic cancer, sepsis-related skeletal muscle wasting, non-small cell lung cancer, acute myeloid leukemia and cancer cachexia .
    C188-9
  • HY-P99241
    Ponsegromab
    1 Publications Verification

    PF 06946860

    		 TGF-beta/Smad Cancer
    Ponsegromab is a Growth differentiation factor 15 (GDF15) inhibitor with human, cynomolgus monkey, and mouse target IC50 values of 0.123 nM, 0.053 nM, and 0.102 nM, respectively . Ponsegromab acts as a chemosensitizer, increases intracellular reactive oxygen species, reduces glutathione levels . Ponsegromab can be used for the research of oxaliplatin-resistant colorectal cancer .
    Ponsegromab
  • HY-13676
    Megestrol acetate
    2 Publications Verification

    		 Progesterone Receptor Autophagy HIV Endocrinology Cancer
    Megestrol acetate is a synthetic and orally active progesteronal agent. Megestrol acetate is effective as an appetite stimulant for wasting syndromes such as cachexia. Megestrol acetate decreases nuclear and cytosol androgen receptors human BPH tissue. Megestrol acetate has the potential for HIV study and downregulates autophagic catabolic pathway .
    Megestrol acetate
  • HY-14734
    Anamorelin
    5+ Cited Publications

    RC-1291; ONO-7643

    		 GHSR Endocrinology Cancer
    Anamorelin (RC-1291) is an orally active Ghrelin receptor agonist with an EC50 of 0.74 nM. Anamorelin can promote appetite, increase body weight, and stimulate the secretion of growth hormone and insulin-like growth factor-1. Anamorelin can be used in the research of anorexia and cancer cachexia .
    Anamorelin
  • HY-12176
    Aliskiren
    10+ Cited Publications

    CGP 60536; CGP60536B; SPP 100

    		 Renin Autophagy Cardiovascular Disease Cancer
    Aliskiren is an orally active, highly potent and selective renin inhibitor, with IC50 of 1.5 nM. Aliskiren can be used for the research of hypertension, cardiovascular diseases and cancer cachexia .
    Aliskiren
  • HY-148349
    PF-07258669
    1 Publications Verification

    		 Melanocortin Receptor Neurological Disease Metabolic Disease
    PF-07258669 is an orally active melanocortin-4 receptor (MC4R) antagonist that antagonizes MC4R with an IC50 of 13 nM (Ki=0.46 nM). PF-07258669 can be used for the research of cachexia, anorexia, or anorexia nervosa .
    PF-07258669
  • HY-100186
    GSK-2881078
    5 Publications Verification

    		 Androgen Receptor Cardiovascular Disease Others Metabolic Disease Inflammation/Immunology Endocrinology Cancer
    GSK-2881078 is an orally active and nonsteroidal selective androgen receptor modulator (SARM) which act as partial AR agonists in androgenic tissues while mainly as complete AR agonists in synthetic metabolic tissues,induces AR-mediated transcriptional activation in PC3(AR)2 cells (EC50 = 3.99 nM) and the effect can be inhibited by the non-steroidal AR antagonist Bicalutamide. GSK-2881078 can be used in research of muscle weakness and cachexia associated with both chronic and acute illness .
    GSK-2881078
  • HY-P5971
    TCMCB07

    Mifomelatide

    		 Melanocortin Receptor Neurological Disease Metabolic Disease
    TCMCB07, a cyclic nonapeptide peptide, is an orally active and brain-penetrant melanocortin receptor 4 (MC4R) antagonist. TCMCB07 plays an important role in cachexia. TCMCB07 has potential transport capabilities .
    TCMCB07
  • HY-12177
    Aliskiren hemifumarate
    10+ Cited Publications

    CGP 60536 hemifumarate; CGP60536B hemifumarate; SPP 100 hemifumarate

    		 Renin Autophagy Cardiovascular Disease Cancer
    Aliskiren (CGP 60536; CGP60536B; SPP 100) hemifumarate is an orally active and selective renin inhibitor, with IC50 of 1.5 nM. Aliskiren hemifumarate can be used for the research of hypertension, cardiovascular diseases and cancer cachexia .
    Aliskiren hemifumarate
  • HY-14820A
    Macimorelin acetate

    EP-1572 acetate; AEZS-130 acetate

    		 GHSR Neurological Disease Endocrinology Cancer
    Macimorelin (EP-1572) acetate, a GH secretagogue, is an orally active GHSR agonist. Macimorelin acetate stimulates GH release. Macimorelin acetate can be used in the research of adult growth hormone deficiency (AGHD), and Cancer anorexia-cachexia syndrome (CACS) .
    Macimorelin acetate
  • HY-14734A
    Anamorelin hydrochloride
    5+ Cited Publications

    RC-1291 hydrochloride; ONO-7643 hydrochloride

    		 GHSR Endocrinology Cancer
    Anamorelin (RC-1291) hydrochloride is an orally active Ghrelin receptor agonist with an EC50 of 0.74 nM. Anamorelin hydrochloride can promote appetite, increase body weight, and stimulate the secretion of growth hormone and insulin-like growth factor-1. Anamorelin hydrochloride can be used in the research of anorexia and cancer cachexia .
    Anamorelin hydrochloride
  • HY-19884B
    Relamorelin TFA
    1 Publications Verification

    RM-131 TFA; BIM-28131 TFA

    		 GHSR Metabolic Disease
    Relamorelin (RM-131) TFA, a pentapeptide ghrelin analog, is a selective ghrelin/growth hormone secretagogue receptor (GHSR) agonist with a Ki of 0.42 nM for GHS-1a receptor. Relamorelin TFA is centrally penetrant. Relamorelin TFA increases growth hormone levels and accelerates gastric emptying. Relamorelin TFA has the potential for cachexia, gastroparesis, and gastric/intestinal dysmobility disorders research .
    Relamorelin TFA
  • HY-129531
    MuRF1-IN-1

    		E1/E2/E3 Enzyme Neurological Disease
    MuRF1-IN-1 is an orally active MuRF1 inhibitor. MuRF1-IN-1 can inhibit the interaction between MuRF1 and titin as well as E3 ligase activity. MuRF1-IN-1 can alleviate skeletal muscle atrophy and dysfunction in cardiac cachexia .
    MuRF1-IN-1
  • HY-164027
    MyoMed 205

    		E1/E2/E3 Enzyme Metabolic Disease Cancer
    MyoMed 205 is an orally active muscle ring finger protein 1 (MuRF1) inhibitor. MyoMed-205 reduces ubiquitination and subsequent proteasomal degradation of muscle proteins by inhibiting MuRF1 activity. MyoMed 205 augments muscle performance, attenuates muscle weight loss and alleviates disease-induced weight loss. MyoMed 205 can be used for the research of cancer cachexia, type 2 diabetes mellitus, and heart failure with preserved ejection fraction .
    MyoMed 205
  • HY-B0580B
    (R)-Ketorolac
    1 Publications Verification

    (+)-Ketorolac

    		 Ras Cancer
    (R)-Ketorolac is an orally active Cdc42 and Rac1 inhibitor. (R)-Ketorolac inhibits GTPase. (R)-Ketorolac alters ovarian cancer cell behaviors critical for invasion and metastasis. (R)-Ketorolac ameliorates cancer-associated cachexia .
    (R)-Ketorolac
  • HY-B1834
    Megestrol

    		Progesterone Receptor Glucocorticoid Receptor Infection Neurological Disease Inflammation/Immunology Cancer
    Megestrol is an orally active glucocorticoid and progesterone receptor agonist. Megestrol can alleviate anorexia, cachexia or unexplained significant weight loss associated with acquired immunodeficiency syndrome (AIDS). Megestrol may cause manifestations similar to those of glucocorticoids and increase the risk of mental disorders .
    Megestrol
  • HY-129692
    Withanone
    1 Publications Verification

    		 iGluR Neurological Disease Cancer
    Withanone is an active ingredient from the roots of Withania somnifera and a GRP75 inhibitor. Withanone has multifunctional neuroprotective effects in alleviating cognitive dysfunction. In neuron-like cells, Withanone can inhibit NMDA-induced excitotoxicity. Withanone can inhibit white adipose tissue browning by blocking the formation of the GRP75-ANT2-UCP1 complex, thereby alleviating cancer-related cachexia. Withanone can be used in the research of tumors and nervous system diseases .
    Withanone
  • HY-13676R
    Megestrol acetate (Standard)
    2 Publications Verification

    		 Reference Standards Progesterone Receptor Autophagy HIV Endocrinology Cancer
    Megestrol acetate (Standard) is the analytical standard of Megestrol acetate. This product is intended for research and analytical applications. Megestrol acetate is a synthetic and orally active progesteronal agent. Megestrol acetate is effective as an appetite stimulant for wasting syndromes such as cachexia. Megestrol acetate decreases nuclear and cytosol androgen receptors human BPH tissue. Megestrol acetate has the potential for HIV study and downregulates autophagic catabolic pathway .
    Megestrol acetate (Standard)
  • HY-78985
    Benzene-1,3,5-tricarboxylic acid

    Trimesic acid

    		 MOFs Others
    Benzene-1,3,5-tricarboxylic acid (Trimesic acid) is a rigid planar small-molecule scaffold and crosslinker. Benzene-1,3,5-tricarboxylic acid induces bicyclic peptides to adopt a planar conformation, so as to maximize surface area and bind to the flat protein surfaces involved in protein-protein interactions. Benzene-1,3,5-tricarboxylic acid forms ionic crosslinks, hydrogen bonds and π-π bonds with chitosan, thereby constructing a hydrogel network. Benzene-1,3,5-tricarboxylic acid endows chitosan hydrogel systems with specific mechanical properties, enabling sustained release of cancer therapeutic drugs including 5-fluorouracil (HY-90006) .
    Benzene-1,3,5-tricarboxylic acid
  • HY-156354
    GPR61 Inverse agonist 1

    		Orphan GPCR Metabolic Disease
    GPR61 Inverse agonist 1 (Compound 1) is a GPR61 inverse agonist (IC50: 11 nM). GPR61 Inverse agonist 1 can be used for research of disorders of metabolism and body weight, such as obesity and cachexia .
    GPR61 Inverse agonist 1
  • HY-161875
    NAT1-IN-1

    		Histone Acetyltransferase Metabolic Disease Cancer
    NAT1-IN-1 (compound 350) is a potent N-acetyltransferase 1 (NAT1)-targeted inhibitor, with an IC50 of 44 nM. NAT1-IN-1 can be used for the research of hypermetabolic diseases such as amyotrophic lateral sclerosis, cancer cachexia, and sepsis .
    NAT1-IN-1
  • HY-N0109R
    Salidroside (Standard)
    Maximum Cited Publications
    44 Publications Verification

    Rhodioloside (Standard)

    		 Prolyl Endopeptidase (PREP) mTOR Apoptosis PINK1/Parkin Reference Standards Cancer
    Salidroside (Standard) is the analytical standard of Salidroside. This product is intended for research and analytical applications. Salidroside (Rhodioloside) is a prolyl endopeptidase inhibitor. Salidroside alleviates cachexia symptoms in mouse models of cancer cachexia via activating mTOR signalling. Salidroside protects dopaminergic neurons by enhancing PINK1/Parkin-mediated mitophagy.
    Salidroside (Standard)
  • HY-P5971A
    TCMCB07 TFA

    		Melanocortin Receptor Metabolic Disease
    TCMCB07 TFA, a cyclic nonapeptide peptide, is an orally active and brain-penetrant melanocortin receptor 4 (MC4R) antagonist. TCMCB07 TFA plays an important role in cachexia .
    TCMCB07 TFA
  • HY-19884
    Relamorelin

    RM-131; BIM-28131

    		 GHSR Metabolic Disease
    Relamorelin (RM-131), a pentapeptide ghrelin analog, is a selective ghrelin/growth hormone secretagogue receptor (GHSR) agonist with a Ki of 0.42 nM for GHS-1a receptor. Relamorelin is centrally penetrant. Relamorelin increases growth hormone levels and accelerates gastric emptying. Relamorelin has the potential for cachexia, gastroparesis, and gastric/intestinal dysmobility disorders research .
    Relamorelin
  • HY-179571
    ZIP14-IN-1

    PPTD

    		 Reactive Oxygen Species (ROS) Ferroptosis Cancer
    ZIP 14-IN-1 (PPTD) is a selective and orally active ZIP14 inhibitor. ZIP 14-IN-1 inhibits ZIP14 while sparing ZIP8 (SLC39A8). ZIP 14-IN-1 efficiently blocks ZIP14-mediated uptake of multiple divalent metals (zinc, iron, manganese and cadmium). ZIP 14-IN-1 binds to a pocket formed at the dimer interface of ZIP14, obstructing the metal transport pathway. ZIP 14-IN-1 effectively reverses the consequent elevation of reactive oxygen species (ROS) and lipid peroxidation, attenuating metal-induced cytotoxicity. ZIP 14-IN-1 can be uses for cancer cachexia research .
    ZIP14-IN-1
  • HY-14820
    Macimorelin

    EP-1572; AEZS-130

    		 GHSR Endocrinology Cancer
    Macimorelin (EP-1572), a GH secretagogue, is an orally active GHSR agonist. Macimorelin stimulates GH release. Macimorelin can be used in the research of adult growth hormone deficiency (AGHD), and Cancer anorexia-cachexia syndrome (CACS) .
    Macimorelin
  • HY-119125
    BMS-317180

    		GHSR Cancer
    BMS-317180 is an orally active and potent growth hormone secretagogue receptor (GHS-R) agonist (EC50=7.9 nM). BMS-317180 stimulates endogenous growth hormone (GH) release. BMS-317180 is promising for research of age-related frailty, osteoporosis, and cancer cachexia .
    BMS-317180
  • HY-19884A
    Relamorelin acetate

    RM-131 acetate; BIM-28131 acetate

    		 GHSR Metabolic Disease
    Relamorelin (RM-131) acetate, a pentapeptide ghrelin analog, is a selective ghrelin/growth hormone secretagogue receptor (GHSR) agonist with a Ki of 0.42 nM for GHS-1a receptor. Relamorelin acetate is centrally penetrant. Relamorelin acetate increases growth hormone levels and accelerates gastric emptying. Relamorelin acetate has the potential for cachexia, gastroparesis, and gastric/intestinal dysmobility disorders research .
    Relamorelin acetate
  • HY-13676S
    Megestrol acetate-d3

    		Isotope-Labeled Compounds Progesterone Receptor Autophagy HIV Endocrinology Cancer
    Megestrol acetate-d3 is the deuterium labeled Megestrol acetate. Megestrol acetate is a synthetic and orally active progesteronal agent. Megestrol acetate is effective as an appetite stimulant for wasting syndromes such as cachexia. Megestrol acetate decreases nuclear and cytosol androgen receptors human BPH tissue. Megestrol acetate has the potential for HIV study and downregulates autophagic catabolic pathway .
    Megestrol acetate-d3
  • HY-12176B
    Aliskiren fumarate

    CGP 60536 fumarate; CGP60536B fumarate; SPP 100 fumarate

    		 Renin Autophagy Cardiovascular Disease Cancer
    Aliskiren fumarate is an orally active, highly potent and selective renin inhibitor, with IC50 of 1.5 nM. Aliskiren fumarate can be used for the research of hypertension, cardiovascular diseases and cancer cachexia .
    Aliskiren fumarate
  • HY-12176A
    Aliskiren hydrochloride

    CGP 60536 hydrochloride; CGP60536B hydrochloride; SPP 100 hydrochloride

    		 Renin Autophagy Cardiovascular Disease Cancer
    Aliskiren (CGP 60536; CGP60536B; SPP 100) hydrochloride is an orally active and selective renin inhibitor, with IC50 of 1.5 nM. Aliskiren hydrochloride can be used for the research of hypertension, cardiovascular diseases and cancer cachexia - .
    Aliskiren hydrochloride
  • HY-12176R
    Aliskiren (Standard)

    CGP 60536 (Standard); CGP60536B (Standard); SPP 100 (Standard)

    		 Reference Standards Renin Autophagy Cardiovascular Disease Cancer
    Aliskiren (Standard) is the analytical standard of Aliskiren. This product is intended for research and analytical applications. Aliskiren is an orally active, highly potent and selective renin inhibitor, with IC50 of 1.5 nM. Aliskiren can be used for the research of hypertension, cardiovascular diseases and cancer cachexia .
    Aliskiren (Standard)
  • HY-12177R
    Aliskiren hemifumarate (Standard)

    CGP 60536 hemifumarate (Standard); CGP60536B hemifumarate (Standard); SPP 100 hemifumarate (Standard)

    		 Renin Autophagy Reference Standards Cardiovascular Disease Cancer
    Aliskiren (hemifumarate) (Standard) is the analytical standard of Aliskiren (hemifumarate). This product is intended for research and analytical applications. Aliskiren (CGP 60536; CGP60536B; SPP 100) hemifumarate is an orally active and selective renin inhibitor, with IC50 of 1.5 nM. Aliskiren hemifumarate can be used for the research of hypertension, cardiovascular diseases and cancer cachexia .
    Aliskiren hemifumarate (Standard)
  • HY-11032
    SM-350300

    		Others Metabolic Disease
    SM-350300 is a glucoprotein. SM-350300 stimulates lipolysis in white adipocytes by activating the cyclic AMP (cAMP) pathway, and upregulates the expression of lipolytic enzymes and uncoupling proteins (UCP1, UCP3) in brown adipose tissue (BAT) and white adipose tissue (WAT). SM-350300 reduces body weight by decreasing carcass fat while increasing lean muscle mass in metabolic disorder models. SM-350300 can be used for the study of metabolic disorders including obesity, type 2 diabetes, and cachexia .
    SM-350300
  • HY-W747043
    Megestrol-d3

    		Isotope-Labeled Compounds Drug Metabolite Inflammation/Immunology
    Megestrol-d3 is the deuterium labeled Megestrol (HY-B1834). Megestrol is a synthetic progestin and used for the treatment of anorexia, cachexia, or an unexplained significant weight loss in patients with an acquired immunodeficiency syndrome diagnosis .
    Megestrol-d3
  • HY-14734B
    Anamorelin Fumarate

    RC-1291 Fumarate; ONO-7643 Fumarate

    		 GHSR Endocrinology Cancer
    Anamorelin (RC-1291) Fumarate is an orally active Ghrelin receptor agonist with an EC50 of 0.74 nM. Anamorelin Fumarate can promote appetite, increase body weight, and stimulate the secretion of growth hormone and insulin-like growth factor-1. Anamorelin Fumarate can be used in the research of anorexia and cancer cachexia .
    Anamorelin Fumarate
  • HY-B1834S1
    Megestrol-d5

    		Isotope-Labeled Compounds Progesterone Receptor Glucocorticoid Receptor Infection Neurological Disease Inflammation/Immunology Cancer
    Megestrol-d5 is the deuterium labeled Megestrol. Megestrol is an orally active glucocorticoid and progesterone receptor agonist. Megestrol can alleviate anorexia, cachexia or unexplained significant weight loss associated with acquired immunodeficiency syndrome (AIDS). Megestrol may cause glucocorticoid-like effects and an increased risk of mental disorders.
    Megestrol-d5
  • HY-B1834R
    Megestrol (Standard)

    		Reference Standards Progesterone Receptor Glucocorticoid Receptor Infection Neurological Disease Inflammation/Immunology Cancer
    Megestrol (Standard) is the analytical standard of Megestrol. This product is intended for research and analytical applications. Megestrol is an orally active glucocorticoid and progesterone receptor agonist. Megestrol can alleviate anorexia, cachexia or unexplained significant weight loss associated with acquired immunodeficiency syndrome (AIDS). Megestrol may cause manifestations similar to those of glucocorticoids and increase the risk of mental disorders.
    Megestrol (Standard)
  • HY-13676S1
    Megestrol acetate-d3-1

    		Isotope-Labeled Compounds Progesterone Receptor Autophagy HIV Endocrinology Cancer
    Megestrol acetate-d3-1 is deuterium labeled Megestrol acetate. Megestrol acetate is a synthetic and orally active progesteronal agent. Megestrol acetate is effective as an appetite stimulant for wasting syndromes such as cachexia. Megestrol acetate decreases nuclear and cytosol androgen receptors human BPH tissue. Megestrol acetate has the potential for HIV study and downregulates autophagic catabolic pathway .
    Megestrol acetate-d3-1
  • HY-14734R
    Anamorelin (Standard)

    RC-1291 (Standard); ONO-7643 (Standard)

    		 Reference Standards GHSR Endocrinology Cancer
    Anamorelin (Standard) (RC-1291 (Standard)) is the analytical standard of Anamorelin (HY-14734). This product is intended for research and analytical applications. Anamorelin (RC-1291) is an orally active Ghrelin receptor agonist with an EC50 of 0.74 nM. Anamorelin can promote appetite, increase body weight, and stimulate the secretion of growth hormone and insulin-like growth factor-1. Anamorelin can be used in the research of anorexia and cancer cachexia .
    Anamorelin (Standard)
  • HY-129692R
    Withanone (Standard)

    		Reference Standards iGluR Neurological Disease Cancer
    Withanone (Standard) is the analytical standard of Withanone (HY-129692). This product is intended for research and analytical applications. Withanone is an active ingredient from the roots of Withania somnifera and a GRP75 inhibitor. Withanone has multifunctional neuroprotective effects in alleviating cognitive dysfunction. In neuron-like cells, Withanone can inhibit NMDA-induced excitotoxicity. Withanone can inhibit white adipose tissue browning by blocking the formation of the GRP75-ANT2-UCP1 complex, thereby alleviating cancer-related cachexia. Withanone can be used in the research of tumors and nervous system diseases .
    Withanone (Standard)
  • HY-P992393
    JMT203

    		TGF-β Receptor Cancer
    JMT203 is a monoclonal antibody against GFRAL and a body weight gain inducer. JMT203 induces early-onset, sustained and progressive body weight gain in cancer cachexia. JMT203 can be used for research related to cancer cachexia .
    JMT203
  • HY-W1142093
    ActRIIB-IN-4

    		TGF-β Receptor Neurological Disease Cancer
    ActRIIB-IN-4 (Compound 10) is an ActRIIB inhibitor with an IC50 of 4.0 nM. ActRIIB-IN-4 enhances muscle grip strength in tumor cachexia mice .
    ActRIIB-IN-4
  • HY-W1142089
    ActRIIB-IN-2

    		TGF-β Receptor Cancer
    ActRIIB-IN-2 is an ActRIIB inhibitor with an IC50 of 1.1 nM. ActRIIB-IN-2 can be used for the research of cancer cachexia .
    ActRIIB-IN-2
  • HY-178999
    Carnosol analog 1

    		Drug Derivative Cancer
    Carnosol analog 1 (Compound 10) is a derivative of carnosol. Carnosol analog 1 attenuates myotube atrophy (67.08% reversal) and adipocyte lipolysis in C26 tumor-conditioned models. Carnosol analog 1 alleviates cachexia-related weight loss without altering tumor progression in C26 tumor-bearing mice. Carnosol analog 1 can be used for the study of cancer cachexia .
    Carnosol analog 1
  • HY-183504
    ActRIIB-IN-3

    		TGF-β Receptor Cancer
    ActRIIB-IN-3 is a ActRIIB inhibitor. ActRIIB-IN-3 inhibits the ActRIIB protein in the MSTN pathway and induces the reversal of skeletal muscle atrophy associated with cancer cachexia. ActRIIB-IN-3 is applicable for the research of cancer cachexia .
    ActRIIB-IN-3
  • HY-183005
    ActRIIB-IN-1

    		TGF-β Receptor Inflammation/Immunology Cancer
    ActRIIB-IN-1, 7-azaindole compound is an orally active activin type II receptor B (ActRIIB) inhibitor with an IC50 of 1.8 nM. ActRIIB-IN-1 can alleviate weight loss, muscle atrophy and decreased muscle strength caused by tumor cachexia, as well as improve appetite. ActRIIB-IN-1 can be used for the research of cancer cachexia .
    ActRIIB-IN-1
  • HY-183106
    MC4R antagonist-2

    		Melanocortin Receptor Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology
    MC4R antagonist-2 is a potent melanocortin 4 receptor (MC4R) antagonist with an IC50 of 0.54 nM. MC4R antagonist-2 can be used for the research of MC4R-mediated conditions, such as cachexia, osteoporosis, neuropathic pain, depression, hypertension, malnutrition-related obesity, and associated inflammatory diseases .
    MC4R antagonist-2
  • HY-182773
    MC4R Antagonist-1

    		Melanocortin Receptor Metabolic Disease
    MC4R Antagonist-1 (compound 1) is an MC4R-selective antagonist (IC50<10 nM). MC4R Antagonist-1 can be used for the research of cachexia, anorexia, anorexia nervosa, involuntary weight loss, failure to thrive, sarcopenia, muscle wasting, muscle weakness, frailty, osteoporosis .
    MC4R Antagonist-1

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: